Finding 34673 (2022-004)

Significant Deficiency Repeat Finding
Requirement
L
Questioned Costs
-
Year
2022
Accepted
2023-08-30

AI Summary

  • Core Issue: Lack of proper supervisory review and approval for grant reporting.
  • Impacted Requirements: Internal controls must include timely and documented reviews to ensure compliance.
  • Recommended Follow-Up: Treasurer should review and document approval of all future grant reports before submission.

Finding Text

Condition: The Association does not have appropriate supervisory review and approval procedures in the grant reporting function within the internal control framework. Criteria: Effective internal control over compliance includes appropriate, timely, and documented supervisory review and approval procedures. Cause: The grant reporting is prepared and submitted by the program manager without documented supervisory review and approval. Effect: The Association is at an increased risk for grant reporting errors or omissions without timely supervisory review and approval. Questioned Costs: N/A Recommendation: We recommend the Treasurer review and approve all future grant reports prior to their submission. The approval should be documented in writing. Views of Responsible Officials: Management concurs with the finding and has developed a plan to correct the finding.

Corrective Action Plan

CONTROLS OVER GRANT REPORTING Department of Health and Human Services 93.788 Management within West Virginia Public Transit Association appreciates and shares the auditors? concern with integrity as it relates to controls over grant reporting. The State Opioid Response Transportation Project Manager will submit all future grant reports to the West Virginia Public Transit Association Treasurer for review prior to submission to grantor. The Treasurer will document approval in writing. This will begin with the quarter ending September 29, 2023.

Categories

Reporting Internal Control / Segregation of Duties

Other Findings in this Audit

  • 34671 2022-002
    - Repeat
  • 34672 2022-003
    - Repeat
  • 34674 2022-001
    - Repeat
  • 34675 2022-001
    - Repeat
  • 34676 2022-002
    - Repeat
  • 34677 2022-003
    - Repeat
  • 34678 2022-004
    Significant Deficiency Repeat
  • 611113 2022-002
    - Repeat
  • 611114 2022-003
    - Repeat
  • 611115 2022-004
    Significant Deficiency Repeat
  • 611116 2022-001
    - Repeat
  • 611117 2022-001
    - Repeat
  • 611118 2022-002
    - Repeat
  • 611119 2022-003
    - Repeat
  • 611120 2022-004
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
93.788 Opioid Str $1.12M